Literature DB >> 1433273

Efficacy of live-attenuated and whole-inactivated simian immunodeficiency virus vaccines against vaginal challenge with virulent SIV.

M L Marthas1, C J Miller, S Sutjipto, J Higgins, J Torten, B L Lohman, R E Unger, R A Ramos, H Kiyono, J R McGhee.   

Abstract

The ability of two vaccine preparations (UV-psoralen inactivated SIV administered intramuscularly and live-attenuated SIV inoculated intravaginally) to prevent genital transmission of virulent SIV in rhesus macaques was tested. Two of six whole-inactivated SIV vaccinated macaques, three of five live-attenuated SIV vaccinated macaques, and four of six controls became persistently infected after two separate intravaginal inoculations with a 50% animal infectious dose of virulent SIV. No association was observed between levels of SIV-specific antibodies in serum or vaginal secretions prior to challenge and subsequent infection with virulent SIV.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1433273

Source DB:  PubMed          Journal:  J Med Primatol        ISSN: 0047-2565            Impact factor:   0.667


  25 in total

1.  Immunization with a live, attenuated simian immunodeficiency virus vaccine leads to restriction of viral diversity in Rhesus macaques not protected from pathogenic challenge.

Authors:  D L Sodora; K E Sheridan; P A Marx; R I Connor
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

2.  An adenovirus-simian immunodeficiency virus env vaccine elicits humoral, cellular, and mucosal immune responses in rhesus macaques and decreases viral burden following vaginal challenge.

Authors:  S L Buge; E Richardson; S Alipanah; P Markham; S Cheng; N Kalyan; C J Miller; M Lubeck; S Udem; J Eldridge; M Robert-Guroff
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

3.  Post-translational intracellular trafficking determines the type of immune response elicited by DNA vaccines expressing Gag antigen of Human Immunodeficiency Virus Type 1 (HIV-1).

Authors:  Aaron Wallace; Kim West; Alan L Rothman; Francis A Ennis; Shan Lu; Shixia Wang
Journal:  Hum Vaccin Immunother       Date:  2013-08-13       Impact factor: 3.452

4.  Rhesus macaques previously infected with simian/human immunodeficiency virus are protected from vaginal challenge with pathogenic SIVmac239.

Authors:  C J Miller; M B McChesney; X Lü; P J Dailey; C Chutkowski; D Lu; P Brosio; B Roberts; Y Lu
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

5.  Immunogenicity of viral vector, prime-boost SIV vaccine regimens in infant rhesus macaques: attenuated vesicular stomatitis virus (VSV) and modified vaccinia Ankara (MVA) recombinant SIV vaccines compared to live-attenuated SIV.

Authors:  Koen K A Van Rompay; Kristina Abel; Patricia Earl; Pamela A Kozlowski; Juliet Easlick; Joseph Moore; Linda Buonocore-Buzzelli; Kimberli A Schmidt; Robert L Wilson; Ian Simon; Bernard Moss; Nina Rose; John Rose; Marta L Marthas
Journal:  Vaccine       Date:  2009-12-06       Impact factor: 3.641

6.  Macaques immunized with HLA-DR are protected from challenge with simian immunodeficiency virus.

Authors:  L O Arthur; J W Bess; R G Urban; J L Strominger; W R Morton; D L Mann; L E Henderson; R E Benveniste
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

7.  Cross-protective immune responses induced in rhesus macaques by immunization with attenuated macrophage-tropic simian immunodeficiency virus.

Authors:  J E Clements; R C Montelaro; M C Zink; A M Amedee; S Miller; A M Trichel; B Jagerski; D Hauer; L N Martin; R P Bohm
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

8.  Control of viremia and maintenance of intestinal CD4(+) memory T cells in SHIV(162P3) infected macaques after pathogenic SIV(MAC251) challenge.

Authors:  Bapi Pahar; Andrew A Lackner; Michael Piatak; Jeffrey D Lifson; Xiaolei Wang; Arpita Das; Binhua Ling; David C Montefiori; Ronald S Veazey
Journal:  Virology       Date:  2009-03-18       Impact factor: 3.616

Review 9.  The rhesus macaque pediatric SIV infection model - a valuable tool in understanding infant HIV-1 pathogenesis and for designing pediatric HIV-1 prevention strategies.

Authors:  Kristina Abel
Journal:  Curr HIV Res       Date:  2009-01       Impact factor: 1.581

10.  Immunity and protection by live attenuated HIV/SIV vaccines.

Authors:  Dominik Wodarz
Journal:  Virology       Date:  2008-06-30       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.